ES2113670T3 - Vacunas contra virus respiratorio sincitial inactivadas. - Google Patents
Vacunas contra virus respiratorio sincitial inactivadas.Info
- Publication number
- ES2113670T3 ES2113670T3 ES94923619T ES94923619T ES2113670T3 ES 2113670 T3 ES2113670 T3 ES 2113670T3 ES 94923619 T ES94923619 T ES 94923619T ES 94923619 T ES94923619 T ES 94923619T ES 2113670 T3 ES2113670 T3 ES 2113670T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- immunogenic composition
- purified
- inactivated
- sincitial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 229940031551 inactivated vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 abstract 1
- HEGSGKPQLMEBJL-RGDJUOJXSA-N octyl alpha-D-glucopyranoside Chemical compound CCCCCCCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RGDJUOJXSA-N 0.000 abstract 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 abstract 1
- 229960000380 propiolactone Drugs 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18551—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
SE PRESENTA UNA COMPOSICION INMUNOGENICA CAPAZ DE PRODUCIR UNA RESPUESTA INMUNE ESPECIFICA PARA EL VIRUS SINCIATIAL RESPIRATORIO (RS) EN UN ANFITRION INMUNIZADO CON LA MISMA, LA COMPOSICION COMPRENDE VIRUS RS PURIFICADO, INSACTIVADO QUE ESTA SUBSTANCIALMENTE LIBRE DE COMPONENTES CELULARES Y DEL SUERO Y QUE NO ES INFECCIOSO, NO ES INMUNOPOTENCIADOR, ES INMUNOGENICO Y ES PROTECTOR. EL VIRUS SE HACE CRECER EN UNA LINEA CELULAR DE CALIDAD DE VACUNA Y EL VIRUS COSECHADO SE PURIFICA BAJO CONDICIONES NO DESNATURALIZADORAS PARA QUE ESTE SUBSTANCIALMENTE LIBRE DE COMPONENTES CELULARES Y DEL SUERO. EL VIRUS RS PURIFICADO SE INACTIVA UTILIZANDO {BE}-PROPIOLACTONA, UN DETERGENTE NO IONICO, PARTICULARMENTE N-OCTIL-{AL}-DGLUCOPYRANOSIDO Y N-OCTIL-{BE}-D-GLUOCOPIRANOSIDO, O ACIDO ASCORBICO, LA COMPOSICION INMUNOGENICA PUEDE FORMULARSE COMO VACUNA PARA LA ADMINISTRACION "IN VIVO" A UN ANFITRION HUMANO. LA COMPOSICION INMUNOGENICA TAMBIEN PUEDE UTILIZARSE EN APLICACIONES DE DIAGNOSTICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10274293A | 1993-08-06 | 1993-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2113670T3 true ES2113670T3 (es) | 1998-05-01 |
Family
ID=22291469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94923619T Expired - Lifetime ES2113670T3 (es) | 1993-08-06 | 1994-08-04 | Vacunas contra virus respiratorio sincitial inactivadas. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7083795B1 (es) |
| EP (1) | EP0714306B1 (es) |
| JP (1) | JP4053587B2 (es) |
| KR (1) | KR100402379B1 (es) |
| CN (1) | CN1103603C (es) |
| AT (1) | ATE164313T1 (es) |
| AU (1) | AU677090B2 (es) |
| BR (1) | BR9407182A (es) |
| CA (1) | CA2167274C (es) |
| DE (1) | DE69409243T2 (es) |
| DK (1) | DK0714306T3 (es) |
| ES (1) | ES2113670T3 (es) |
| GR (1) | GR3026619T3 (es) |
| RU (1) | RU2142817C1 (es) |
| WO (1) | WO1995004545A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4243491A1 (de) * | 1992-12-22 | 1994-06-23 | Behringwerke Ag | Verfahren zur Reinigung und Anreicherung von Rubella-Virus |
| RU2289425C2 (ru) * | 2004-12-09 | 2006-12-20 | Михаил Петрович Костинов | Способ профилактики заболеваний лор-органов и органов дыхательной системы, обусловленных вирусной и неспецифической бактериальной флорой у детей раннего возраста, рожденных от вич-инфицированных матерей |
| CN106008716B (zh) * | 2010-07-07 | 2019-08-13 | 人工细胞科技公司 | 呼吸道合胞病毒抗原组合物和方法 |
| DK3728287T3 (da) * | 2017-12-19 | 2024-06-10 | CSL Behring Lengnau AG | Proteinoprensning og virusinaktivering med alkylglycosider |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| CN114828885A (zh) * | 2019-12-10 | 2022-07-29 | 瑞普利金公司 | 制备病毒载体的方法 |
| EP4281065A1 (en) | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1188985A (en) * | 1980-07-01 | 1985-06-18 | National Research Development Corporation | Production of viral antigens |
| US4591505A (en) * | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
| US4664912A (en) | 1984-10-01 | 1987-05-12 | Wiktor Tadeusz J | Process for the large scale production of rabies vaccine |
| US4790987A (en) * | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| DE3886332T2 (de) * | 1987-09-28 | 1994-03-31 | Beecham Inc | Inaktivierung von Viren und Bakterien. |
| US5200179A (en) * | 1987-09-28 | 1993-04-06 | Beecham Group P.L.C. | Vaccine |
| US5223254A (en) * | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
| GB8914968D0 (en) | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
| TW275632B (es) * | 1992-04-21 | 1996-05-11 | American Cyanamid Co | |
| IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
-
1994
- 1994-08-04 RU RU96105905A patent/RU2142817C1/ru not_active IP Right Cessation
- 1994-08-04 KR KR1019960700607A patent/KR100402379B1/ko not_active Expired - Fee Related
- 1994-08-04 BR BR9407182A patent/BR9407182A/pt not_active Application Discontinuation
- 1994-08-04 AT AT94923619T patent/ATE164313T1/de active
- 1994-08-04 AU AU73801/94A patent/AU677090B2/en not_active Ceased
- 1994-08-04 ES ES94923619T patent/ES2113670T3/es not_active Expired - Lifetime
- 1994-08-04 CA CA002167274A patent/CA2167274C/en not_active Expired - Fee Related
- 1994-08-04 US US08/583,124 patent/US7083795B1/en not_active Expired - Fee Related
- 1994-08-04 EP EP94923619A patent/EP0714306B1/en not_active Expired - Lifetime
- 1994-08-04 CN CN94193703A patent/CN1103603C/zh not_active Expired - Lifetime
- 1994-08-04 WO PCT/CA1994/000425 patent/WO1995004545A1/en not_active Ceased
- 1994-08-04 DE DE69409243T patent/DE69409243T2/de not_active Expired - Lifetime
- 1994-08-04 JP JP50612395A patent/JP4053587B2/ja not_active Expired - Fee Related
- 1994-08-04 DK DK94923619T patent/DK0714306T3/da active
-
1998
- 1998-04-10 GR GR980400815T patent/GR3026619T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0714306A1 (en) | 1996-06-05 |
| DE69409243D1 (de) | 1998-04-30 |
| RU2142817C1 (ru) | 1999-12-20 |
| CA2167274A1 (en) | 1995-02-16 |
| EP0714306B1 (en) | 1998-03-25 |
| DK0714306T3 (da) | 1998-10-19 |
| AU677090B2 (en) | 1997-04-10 |
| ATE164313T1 (de) | 1998-04-15 |
| DE69409243T2 (de) | 1998-08-06 |
| BR9407182A (pt) | 1996-09-17 |
| CA2167274C (en) | 2007-11-27 |
| GR3026619T3 (en) | 1998-07-31 |
| JP4053587B2 (ja) | 2008-02-27 |
| AU7380194A (en) | 1995-02-28 |
| CN1103603C (zh) | 2003-03-26 |
| US7083795B1 (en) | 2006-08-01 |
| JPH09501912A (ja) | 1997-02-25 |
| KR100402379B1 (ko) | 2004-03-24 |
| KR960703618A (ko) | 1996-08-31 |
| CN1133013A (zh) | 1996-10-09 |
| WO1995004545A1 (en) | 1995-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| BR9510263A (pt) | Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas | |
| CA2121241A1 (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
| DK0777490T3 (da) | Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans | |
| HU229368B1 (en) | Novel vaccine composition | |
| WO2004001007A3 (en) | Buffered formulations for concentrating antibodies and methods of use thereof | |
| MX9306841A (es) | Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos. | |
| FI905184A0 (fi) | Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3. | |
| DK0692028T3 (da) | Farmaceutiske præparater baseret på papillomvira | |
| ES2113670T3 (es) | Vacunas contra virus respiratorio sincitial inactivadas. | |
| ES533111A0 (es) | Un metodo de preparar una vacuna viva | |
| SE8005824L (sv) | Vaccin av hudparvovirus samt forfarande for dess framstellning | |
| DE69940406D1 (de) | Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält | |
| NO950483L (no) | Vaksine mot hepatitt-A | |
| EP0480949A1 (en) | PRODUCTION OF A VIRUS AND CLEANING OF VIRUS COATING PROTEINS FOR VACCINE USE. | |
| ATE220067T1 (de) | 4-(2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl)- - cyclopenten-1-methanol-succinat als antivirales mittel | |
| ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| ATE354370T1 (de) | Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen | |
| ES379641A1 (es) | Procedimiento de produccion de antigenos inactivos para preparados farmaceuticos. | |
| WO1999053950A3 (en) | Live vaccines and methods of treatment therewith | |
| AU5573196A (en) | A pluripotent vaccine against enveloped viruses | |
| DK56389A (da) | Forhindring og behandling af retroviralt frembragte sygdomme | |
| HUP9700975A2 (hu) | Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok | |
| Lestari et al. | Prospect of dengue vaccine development with halal process-based technology | |
| van der Noordaa et al. | Primary vaccination with an attenuated strain of vaccinia virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 714306 Country of ref document: ES |